Skip to main content

Table 1 Patient characteristics at the beginning of the study by baseline iPTH level, all 10 countries

From: Impact of mineral and bone disorder on healthcare resource use and associated costs in the European Fresenius medical care dialysis population: a retrospective cohort study

  Baseline iPTH*, pg/mL Total
< 75 ≥ 75 – < 150 ≥ 150 – ≤ 300 > 300 – ≤ 600 > 600 > 800
N patients 1217 1365 1690 1343 754 472 6369
Males, n (%) 641 (53) 809 (59) 1019 (60) 767 (57) 394 (52) 233 (49) 3630 (57)
Age, years 63.6 (14.7) 64.7 (14.1) 64.2 (14.2) 62.0 (14.8) 58.2 (15.7) 57.5 (15.6) 63.0 (14.7)
Dialysis vintage, months 43.9 (52.7) 37.8 (47.2) 40.9 (53.0) 49.0 (62.2) 66.5 (64.8) 70.6 (64.9) 45.5 (56.0)
History, n (%)
  Diabetes 352 (29) 404 (30) 447 (26) 276 (21) 102 (14) 56 (12) 1581 (25)
  CVD 978 (80) 1075 (79) 1302 (77) 1020 (76) 589 (78) 368 (78) 4964 (78)
CKD aetiology, n (%)
  Hypertension/vascular 167 (14) 189 (14) 249 (15) 189 (14) 92 (12) 64 (14) 886 (14)
  Glomerulonephritis 196 (16) 234 (17) 263 (16) 229 (17) 146 (19) 95 (20) 1068 (17)
  Diabetes 208 (17) 208 (15) 268 (16) 153 (11) 54 (7) 27 (6) 891 (14)
  Tubulo-interstitial 178 (15) 187 (14) 220 (13) 171 (13) 120 (16) 80 (17) 876 (14)
  Polycystic kidney disease 60 (5) 73 (5) 100 (6) 83 (6) 67 (9) 43 (9) 383 (6)
  Miscellaneous 37 (3) 40 (3) 78 (5) 61 (5) 34 (5) 20 (4) 250 (4)
  Unknown 257 (21) 309 (23) 392 (23) 348 (26) 190 (25) 116 (25) 1496 (23)
  Missing 114 (9) 125 (9) 120 (7) 109 (8) 51 (7) 27 (6) 519 (8)
  1. CKD, chronic kidney disease; CVD, cardiovascular disease; iPTH, intact parathyroid hormone.
  2. *Mean iPTH during 3-month baseline period.
  3. Calculated from initiation of dialysis to the start of the 3-month baseline period.
  4. Values are mean (SD) unless specified otherwise.